Abstract
Recent focus on early detection and intervention in psychosis has renewed interest in subtle psychopathology beyond positive and negative symptoms. Such self-experienced sub-clinical disturbances are described in detail by the basic symptom concept. This review will give an introduction into the concept of basic symptoms and describe the development of the current instruments for their assessment, the Schizophrenia Proneness Instrument, Adult (SPI-A) and Child and Youth version (SPI-CY), as well as of the two at-risk criteria: the at-risk criterion Cognitive-Perceptive Basic Symptoms (COPER) and the high-risk criterion Cognitive Disturbances (COGDIS). Further, an overview of prospective studies using both or either basic symptom criteria and transition rates related to these will be given, and the potential benefit of combining ultra-high risk criteria, particularly attenuated psychotic symptoms, and basic symptom criteria will be discussed. Finally, their prevalence in psychosis patients, i.e. the sensitivity, as well as in general population samples will be described. It is concluded that both COPER and COGDIS are able to identify subjects at a high risk of developing psychosis. Further, they appear to be sufficiently frequent prior to onset of the first psychotic episode as well as sufficiently rare in persons of general population to be considered as valuable for an early detection of psychosis.
Keywords: Psychosis, prediction, early detection, basic symptoms, COGDIS, COPER, Schizophrenia Proneness Instrument, climacteric period, frank psychosis, Spearman's rank correlation
Current Pharmaceutical Design
Title: Basic Symptoms and the Prediction of First-Episode Psychosis
Volume: 18 Issue: 4
Author(s): Frauke Schultze-Lutter, Stephan Ruhrmann, Paolo Fusar-Poli, Andreas Bechdolf, Benno G. Schimmelmann and Joachim Klosterkotter
Affiliation:
Keywords: Psychosis, prediction, early detection, basic symptoms, COGDIS, COPER, Schizophrenia Proneness Instrument, climacteric period, frank psychosis, Spearman's rank correlation
Abstract: Recent focus on early detection and intervention in psychosis has renewed interest in subtle psychopathology beyond positive and negative symptoms. Such self-experienced sub-clinical disturbances are described in detail by the basic symptom concept. This review will give an introduction into the concept of basic symptoms and describe the development of the current instruments for their assessment, the Schizophrenia Proneness Instrument, Adult (SPI-A) and Child and Youth version (SPI-CY), as well as of the two at-risk criteria: the at-risk criterion Cognitive-Perceptive Basic Symptoms (COPER) and the high-risk criterion Cognitive Disturbances (COGDIS). Further, an overview of prospective studies using both or either basic symptom criteria and transition rates related to these will be given, and the potential benefit of combining ultra-high risk criteria, particularly attenuated psychotic symptoms, and basic symptom criteria will be discussed. Finally, their prevalence in psychosis patients, i.e. the sensitivity, as well as in general population samples will be described. It is concluded that both COPER and COGDIS are able to identify subjects at a high risk of developing psychosis. Further, they appear to be sufficiently frequent prior to onset of the first psychotic episode as well as sufficiently rare in persons of general population to be considered as valuable for an early detection of psychosis.
Export Options
About this article
Cite this article as:
Schultze-Lutter Frauke, Ruhrmann Stephan, Fusar-Poli Paolo, Bechdolf Andreas, G. Schimmelmann Benno and Klosterkotter Joachim, Basic Symptoms and the Prediction of First-Episode Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316064
DOI https://dx.doi.org/10.2174/138161212799316064 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Special Invited Article Concussion, Sports and Psychiatry
Adolescent Psychiatry Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Current Drug Metabolism Beta-Emitting Radionuclides for Peptide Receptor Radionuclide Therapy
Current Topics in Medicinal Chemistry Induced Pluripotent Stem Cells as a Model for Therapy Personalization of Pediatric Patients: Disease Modeling and Drug Adverse Effects Prevention
Current Medicinal Chemistry Protein Structure Based Strategies for Antigen Discovery and Vaccine Development Against Malaria and Other Pathogens
Endocrine, Metabolic & Immune Disorders - Drug Targets Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Aldose Reductase, Still a Compelling Target for Diabetic Neuropathy
Current Drug Targets Pharmacological Inhibition of Interleukin-8 (CXCL8) as a New Approach for the Prevention and Treatment of Several Human Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design